Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response ...

Separately, Rakovina Therapeutics expects to receive the first synthesized drug candidates from its second AI-driven drug discovery program targeting ATR.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...

A meta-analysis of 43 trials identifies key CBT components, including third-wave therapy and organizational strategies, as ...

Rheumatoid arthritis (RA) is an autoimmune disorder affecting millions worldwide, causing chronic inflammation, debilitating ...

Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal patches and plaques). It affects about 2% of the population and is mediated ...

University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

This Rapid Response activity includes coverage of the latest data on neurostimulation agents for DED management from a recent ophthalmology conference that took place in Chicago, October 2024.